Connect with us

Company News

CONMED Corporation announces first quarter 2024 financial results

CONMED Corporation announced financial results for the first quarter ended March 31, 2024.

“2024 is off to a solid start as the quarter delivered our expected top- and bottom-line growth and margin expansion,” commented Curt R. Hartman, CONMED’s Chair of the Board, President, and Chief Executive Officer. “We remain well positioned with a compelling and diverse portfolio to drive continued growth across the markets we serve.”

2024 outlook
Based on current foreign currency exchange rates, the Company now expects incremental revenue currency headwinds of approximately $10 million. Therefore, full-year reported revenue is now expected to be between $1.330 billion and $1.355 billion, compared to the prior guidance range of between $1.340 billion and $1.365 billion.

Primarily as a result of these same incremental foreign currency headwinds, the Company now expects full-year adjusted diluted net earnings per share(2) in the range of $4.25 to $4.35, compared to its prior range of $4.30 to $4.40.
MB Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!